Rituximab vs Ocrelizumab in Relapsing-Remitting Multiple SclerosisIzanne Roos, Vincent Van Pesch, Cavit Boz et al.|JAMA Neurology|2023Cited by 62
Natalizumab Versus Fingolimod in Patients with Relapsing-Remitting Multiple Sclerosis: A Subgroup Analysis From Three International CohortsSifat Sharmin, Éric Berger, Mathilde Lefort et al.|CNS Drugs|2021Cited by 12
Disease-modifying treatment and disability progression in subclasses of patients with primary progressive MS: results from the Big MS Data NetworkJohannes Lorscheider, Alessio Signori, Suvitha Subramaniam et al.|Journal of Neurology Neurosurgery & Psychiatry|2024Cited by 4